Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 476

STATEMENT of facts re #473 MOTION for Summary Judgment That Claim 10 of the '933 Patent is Invalid on the Ground of Failure to Comply with Claim Differentiation Under Section 112, Paragraph 4 (Pursuant to Local Rule 56.1). (Toms, Keith)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 476

Case 1:05-cv-12237-WGY

Document 476

Filed 06/11/2007

Page 1 of 3

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

AMGEN, INC., Plaintiff, Civil Action No. 05-12237 WGY

U.S. District Judge Young v. F. HOFFMANN-LA ROCHE LTD, a Swiss Company, ROCHE DIAGNOSTICS GmbH, a German Company and HOFFMANN-LA ROCHE INC., a New Jersey Corporation, Defendants. DEFENDANTS' RULE 56.1 STATEMENT OF UNDISPUTED MATERIAL FACTS IN SUPPORT OF DEFENDANTS' MOTION FOR SUMMARY JUDGMENT THAT CLAIM 10 OF THE `933 PATENT IS INVALID ON THE GROUNDS OF FAILURE TO COMPLY WITH CLAIM DIFFERENTIATION UNDER § 112, ¶ 4 Defendants F. Hoffmann-La Roche Ltd, Roche Diagnostics GmbH, and Hoffmann-La Roche, Inc. ("Roche") submit the following statement of undisputed material facts pursuant to LR 56.1 in support of their motion for summary judgment that claim 10 of U.S. Patent No. 5,547,933 (hereinafter "the `933 patent") is invalid on the grounds of failure to comply with claim differentiation under 35 U.S.C. § 112, ¶ 4. 1. Claim 9 of the `933 patent reads as follows: "A pharmaceutical composition comprising an effective amount a glycoprotein product effective for erythropoietin therapy according to claim 1, 2, 3, 4, 5 or 6 and a pharmaceutically acceptable diluent, adjuvant or carrier." (Suh Decl., Ex. A, `933, column 39, ll.1-4) 2. On April 17, 2007, this Court tentatively held that "a pharmaceutical composition comprising," as recited in claim 9, means "a composition suitable for administration

1
Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 476

Filed 06/11/2007

Page 2 of 3

to humans containing a diluent, adjuvant or carrier." (Suh Decl., Ex. B, Claim Construction Hearing, April 17, 2007, pgs. 76:24-77:4. (emphasis added). 3. Claim 10 of the `933 patent, which is depends upon claim 9, reads as follows: "A method of providing erythropoietin therapy to a mammal comprising administering an effective amount of a pharmaceutical composition of claim 9." (Suh Decl., Ex. A `933, column 39, ll. 5-7) (emphasis added)

2

Case 1:05-cv-12237-WGY

Document 476

Filed 06/11/2007

Page 3 of 3

Dated: June 11, 2007 Boston, Massachusetts

Respectfully submitted, F. HOFFMANN-LA ROCHE LTD, ROCHE DIAGNOSTICS GMBH, and HOFFMANN-LA ROCHE INC. By its attorneys, /s/ Keith E. Toms Leora Ben-Ami (pro hac vice) Patricia A. Carson (pro hac vice) Thomas F. Fleming (pro hac vice) Howard S. Suh (pro hac vice) Christopher T. Jagoe (pro hac vice) Krista M. Rycroft (pro hac vice) Peter Fratangelo (BBO# 639775) KAYE SCHOLER LLP 425 Park Avenue New York, New York 10022 Tel. [phone] and Lee Carl Bromberg (BBO# 058480) Julia Huston (BBO# 562160) Keith E. Toms (BBO# 663369) Nicole A. Rizzo (BBO# 663853) BROMBERG & SUNSTEIN LLP 125 Summer Street Boston, MA 02110 Tel. [phone] [e-mail]

CERTIFICATE OF SERVICE I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on the above date. /s/ Keith E. Toms Keith E. Toms

3